Proteases as activators for cytotoxic prodrugs in antitumor therapy

Cancer Genomics and Proteomics

Volumn 11, Issue 2, 2014, Pages 67-80

  Weidle, Ulrich H ^a   Tiefenthaler, Georg ^a   Georges, Guy ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Anthrax toxin; Antibody directed enzyme prodrug therapy; Antibody drug conjugates; Cytotoxic receptor ligand(s); Granzyme B; Probody; Review; Thapsigargin

Indexed keywords

ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOXYPEPTIDASE G2; CATHEPSIN B; CETUXIMAB; CYCLOSPORIN; DIPHTHERIA TOXIN; DOXORUBICIN; FAS LIGAND; GELATINASE A; GELATINASE B; GRANZYME B; INTERSTITIAL COLLAGENASE; KALLIKREIN; MATRIPTASE; MATRIX METALLOPROTEINASE 14; METHOTREXATE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PRODRUG; PROTEINASE; PSEUDOMONAS EXOTOXIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; THAPSIGARGIN; TRASTUZUMAB; UROKINASE; VASCULAR CELL ADHESION MOLECULE 1; VORSETUZUMAB MAFODOTIN; CTSB PROTEIN, HUMAN; GRANZYME; GZMB PROTEIN, HUMAN; MATRIX METALLOPROTEINASE; SERINE PROTEINASE; ST14 PROTEIN, HUMAN;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; BACILLUS ANTHRACIS; BREAST CANCER; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CYTOTOXICITY; DRUG ACTIVATION; DRUG CONJUGATION; DRUG EXTRAVASATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LOCALIZATION; HODGKIN DISEASE; HUMAN; IC 50; IMMUNOFLUORESCENCE; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PATHOGENESIS; PLASMA HALF LIFE; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROTEIN DEGRADATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSIN B; GRANZYMES; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; PRODRUGS; PROTEOLYSIS; SERINE ENDOPEPTIDASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84901472324     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. López-Otín C and Matrisian LM: Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808, 2007.
2. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387-2392, 2002.
3. Overall CM and López-Otín C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672, 2002.
4. Hadler-Olsen E, Winberg JO and Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 34: 2041-2051, 2013.
5. Vartak DG and Gemeinhart RA: Matrix metalloproteases: Underutilized targets for drug delivery. J Drug Target 15: 1-20, 2007.
6. Mohamed MM and Sloane BF: Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 6: 764-775, 2006.
7. D'Alessio S and Blasi F: The urokinase receptor as an entertainer of signal transduction. Front Biosci (Landmark Ed) 14: 4575- 4587, 2009.
8. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997.
9. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA and Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428-2433, 1996.
10. Blasi F and Carmeliet P: uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943, 2002.
11. Oikonomopoulou K, Diamandis EP and Hollenberg MD: Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem 391: 299-310, 2010.
12. Murphy G: The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer 8: 929-941, 2008.
13. Benes P, Vetvicka V and Fusek M: Cathepsin D-many functions of one aspartic protease. Crit Rev Oncol Hematol 68: 12-28, 2008.
14. Koblinski JE, Ahram M and Sloane BF: Unraveling the role of proteases in cancer. Clin Chim Acta 291: 113-135, 2000.
15. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985.
16. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A and Foidart JM: Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405: 157-162, 1997.
17. Choi KY, Swierczewska M, Lee S and Chen X: Protease-activated drug development. Theranostics 2: 156-178, 2012.
18. Seymour LW: Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187, 1992.
19. Duncan R, Kopecek J, Rejmanová P and Lloyd JB: Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim Biophys Acta 755: 518-521, 1983.
20. Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J and Duncan R: Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer 70: 636-641, 1994.
21. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R and Cassidy J: Phase II studies of polymerdoxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34: 1629-1636, 2009.
22. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S and Kerr DJ: Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676, 2002.
23. Shaffer SA, Baker-Lee C, Kennedy J, Lai MS, de Vries P, Buhler K and Singer JW: In vitro and in vivo metabolism of paclitaxel poliglumex: I dentification of metabolites and active proteases. Cancer Chemother Pharmacol 59: 537-548, 2007.
24. Chipman SD, Oldham FB, Pezzoni G and Singer JW: Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine 1: 375-383, 2006.
25. Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW and Bonomi P: Phase III trial comparing paclitaxel poliglumex vs. docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 98: 1608-1613, 2008.
26. Ducry L and Stump B: Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21: 5-13, 2010.
27. Sassoon I and Blanc V: Antibody-drug conjugate (ADC) clinical pipeline: A review. Methods Mol Biol 1045: 1-27, 2013.
28. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS and Blättler WA: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66: 4426-4433, 2006.
29. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blättler WA and Chari RV: Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49: 4392-4408, 2006.
30. Carter PJ and Senter PD: Antibody-drug conjugates for cancer therapy. Cancer J 14: 154-169, 2008.
31. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C and Corvaïa N: The next generation of antibody-drug conjugates comes of age. Discov Med 10: 329-339, 2010.
32. Senter PD and Sievers EL: The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30: 631-637, 2012.
33. Minich SS: Brentuximab vedotin: A new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother 46: 377-383, 2012.
34. Naumovski L and Junutula JR: Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12: 248-257, 2010.
35. Keir CH and Vahdat LT: The use of an antibody-drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 12: 259-263, 2012.
36. Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K and Hearing VJ: Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J 24: 1616-1629, 2010.
37. Wang X, Ma D, Olson WC and Heston WD: In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10: 1728-1739, 2011.
38. Akhtar NH, Pail O, Saran A, Tyrell L and Tagawa ST: Prostate-specific membrane antigen-based therapeutics. Adv Urol 973820, 2012.
39. Andrady C, Sharma SK and Chester KA: Antibody-enzyme fusion proteins for cancer therapy. Immunotherapy 3: 193-211, 2011.
40. Tietze LF and Schmuck K: Prodrugs for targeted tumor therapies: Recent developments in ADEPT, GDEPT and PMT. Curr Pharm Des 17: 3527-3547, 2011.
41. Melton RG and Sherwood RF: Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 88: 153-165, 1996.
42. Bagshawe KD: Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther 6: 1421-1431, 2006.
43. Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bisset GM and Jarman M: Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 33: 677-681, 1990.
44. Medzihradszky KF, Spencer DI, Sharma SK, Bhatia J, Pedley RB, Read DA, Begent RH and Chester KA: Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 14: 27-37, 2004.
45. Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH and Chester KA: Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res 11: 814-825, 2005.
46. Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA and Begent RH: A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12: 6509-6516, 2006.
47. Bagshawe KD and Sharma SK: Cyclosporine delays host immune response to antibody-enzyme conjugate in ADEPT. Transplant Proc 28: 3156-3158, 1996.
48. Chester KA, Baker M and Mayer A: Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol 1: 549-559, 2005.
49. Denmeade SR and Isaacs JT: Engineering enzymatically activated 'molecular grenades' for cancer. Oncotarget 3: 666-667, 2012.
50. Christensen SB, Skytte DM, Denmeade SR, Dionne C, Møller JV, Nissen P and Isaacs JT: A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem 9: 276-294, 2009.
51. 2+-ATPase. Proc Natl Acad Sci USA 87: 2466-2470, 1990.
52. Breckenridge DG, Germain M, Mathai JP, Nguyen M and Shore GC: Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22: 8608-8618, 2003.
53. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB and Isaacs JT: Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 95: 990-1000, 2003.
54. Christensen SB, Andersen A, Kromann H, Treiman M, Tombal B, Denmeade S and Isaacs JT: Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 7: 1273-1280, 1999.
55. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB and Isaacs JT: Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 4: 140ra86, 2012.
56. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B and Heston WD: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2: 1445-1451, 1996.
57. Carter RE, Feldman AR and Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749-753, 1996.
58. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD and Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5: 2674-2681, 1999.
59. Brennen WN, Isaacs JT and Denmeade SR: Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 11: 257-266, 2012.
60. Wolf BB, Quan C, Tran T, Wiesmann C and Sutherlin D: On the edge of validation-cancer protease fibroblast activation protein. Mini Rev Med Chem 8: 719-727, 2008.
61. Brennen WN, Rosen DM, Wang H, Isaacs JT and Denmeade SR: Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 104: 1320-1334, 2012.
62. Olsson AY, Bjartell A, Lilja H and Lundwall A: Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer 113: 290-297, 2005.
63. Otto A, Bär J and Birkenmeier G: Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein. J Urol 159: 297-303, 1998.
64. Mikolajczyk SD, Millar LS, Kumar A and Saedi MS: Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 34: 44-50, 1998.
65. Eggermont AM and ten Hagen TL: Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 3: 359-367, 2001.
66. Wajant H, Gerspach J and Pfizenmaier K: Tumor therapeutics by design: Targeting and activation of death receptors. Cytokine Growth Factor Rev 16: 55-76, 2005.
67. Kelly T: Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8: 51-58, 2005.
68. Wüest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D and Pfizenmaier K: TNF-Selectokine: A novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 21: 4257-4265, 2002.
69. Gerspach J, Müller D, Münkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H and Pfizenmaier K: Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ 13: 273-284, 2006.
70. Gerspach J, Németh J, Münkel S, Wajant H and Pfizenmaier K: Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol Immunother 55: 1590-1600, 2006.
71. Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K and Wajant H: Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 14: 765-774, 2007.
72. Hristova K, Dempsey CE and White SH: Structure, location, and lipid perturbations of melittin at the membrane interface. Biophys J 80: 801-811, 2001.
73. Holle L, Song W, Holle E, Wei Y, Wagner T and Yu X: A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol 22: 93-98, 2003.
74. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, Cattaneo R, Russell SJ and Vile RG: Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 60: 1492-1497, 2000.
75. Johnson KJ, Peng KW, Allen C, Russell SJ and Galanis E: Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Gene Ther 10: 725-732, 2003.
76. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ and Galanis E: Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med 6: 1216-1227, 2004.
77. Liu S, Schubert RL, Bugge TH and Leppla SH: Anthrax toxin: structures, functions and tumour targeting. Expert Opin Biol Ther 3: 843-853, 2003.
78. Abrami L, Liu S, Cosson P, Leppla SH and van der Goot FG: Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol 160: 321-328, 2003.
79. Cryan LM and Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) 16: 1574-1588, 2011.
80. Shapira A and Benhar I: Toxin-based therapeutic approaches. Toxins 2: 2519-2583, 2010.
81. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD and Vande Woude GF. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737, 1998.
82. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS and Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 99: 3052-3057, 2002.
83. Liu S, Netzel-Arnett S, Birkedal-Hansen H and Leppla SH: Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 60: 6061-6067, 2000.
84. Arora N, Klimpel KR, Singh Y and Leppla SH: Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem 267: 15542-15548, 1992.
85. Milne JC, Blanke SR, Hanna PC and Collier RJ: Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol Microbiol 15: 661-666, 1995.
86. Arora N and Leppla SH: Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun 62: 4955-4961, 1994.
87. Liu S, Bugge TH and Leppla SH: Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 276 : 17976-17984, 2001.
88. Weidle UH, Georges G and Brinkmann U: Fully human targeted cytotoxic fusion proteins: New anticancer agents on the horizon. Cancer Genomics Proteomics 9 : 119-133, 2012.
89. Hehmann-Titt G, Schiffer S, Berges N, Melmer G and Barth S: Improving the therapeutic potential of human granzyme B for targeted cancer therapy. Antibodies 2: 19-49, 2013.
90. Oberoi P, Jabulowsky RA and Wels WS: Selective induction of cancer cell death by targeted granzyme B. Antibodies 2: 130-151, 2013.
91. Kurschus FC and Jenne DE: Delivery and therapeutic potential of human granzyme B. Immunol Rev 235: 159-171, 2010.
92. Rosenblum MG and Barth S: Development of novel, highly cytotoxic fusion constructs containing granzyme B: Unique mechanisms and functions. Curr Pharm Des 15: 2676-2692, 2009.
93. Losasso V, Schiffer S, Barth S and Carloni P: Design of human granzyme B variants resistant to serpin B9. Proteins 80: 2514-2522, 2012.
94. Bird CH, Sun J, Ung K, Karambalis D, Whisstock JC, Trapani JA and Bird PI: Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol Cell Biol 25 : 7854-7867, 2005.
95. Jabulowsky RA, Oberoi P, Bähr-Mahmud H, Dälken B and Wels WS: Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein. Bioconjug Chem 23: 1567-1576, 2012.
96. Kurschus FC, Fellows E, Stegmann E and Jenne DE: Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Ntl Acad Sci USA 105: 13799-13804, 2008
97. Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, Lilie H and Jenne DE: Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett 562 : 87-92, 2004.
98. Keller J, Heisler I, Tauber R and Fuchs H: Development of a novel molecular adapter for the optimization of immunotoxins. J Control Release 74: 259-261, 2001.
99. Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN and Rosenblum MG: Construction and characterization of novel, completely human serine protease therapeutics targeting HER2/NEU. Mol Cancer Ther 12: 979-991, 2013.
100. Hetzel C, Bachran C, Tur MK, Fuchs H and Stöcker M: Improved immunotoxins with novel functional elements. Curr Pharm Des 15: 2700-2711, 2009.
101. Heisler I, Keller J, Tauber R, Sutherland M and Fuchs H: A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. Int J Cancer 103: 277-282, 2003.
102. Säälik P, Elmquist A, Hansen M, Padari K, Saar K, Viht K, Langel U and Pooga M: Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug Chem 15: 1246-1253, 2004.
103. Jones AT: Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm 354: 34-38, 2008.
104. Fuchs H, Bachran C, Heisler I and Sutherland M: A closer look at protein transduction domains as a tool in drug delivery. Curr Nanosci 1: 117-124, 2005.
105. Hudson TH and Neville DM Jr: Enhancement of immunotoxin action: manipulation of the cellular routing of proteins. Cancer Treat Res 37: 371-389, 1988.
106. Fuchs H, Bachran C, Li T, Heisler I, Dürkop H and Sutherland M: A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. J Control Release 117: 342-350, 2007.
107. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S and Stöcker M: Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 31: 370-376, 2008.
108. Hansel TT, Kropshofer H, Singer T, Mitchell JA and George AJ: The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9: 325-338, 2010.
109. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K and Plowman GD: Chronic DLL4 blockade induces vascular neoplasms. Nature 463: E6-7, 2010.
110. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan M, Zha J, Callahan CA, Hymowitz SG and Siebel CW: Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052-1057, 2010.
111. Li JL, Jubb AM and Harris AL: Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol 6: 1099-1103, 2010.
112. Kamba T and McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795, 2007.
113. Segaert S and Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16: 1425-1433, 2005.
114. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR and van Dongen GA: A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12: 6064-6072, 2006.
115. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL and Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285, 2006.
116. Perez EA: Cardiac toxicity of ErbB2-targeted therapies: What do we know? Clin Breast Cancer 8(Suppl 3): S114-120, 2008.
117. Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E and Daugherty PS: Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release 161: 804-812, 2012.
118. LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF and Craik CS: Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci USA 110 : 93-98, 2013.
119. Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EEM, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, Sagert JG, Hofstetter DR, Han F, Gee J, Flandez J, Markham K, Nguyen M, Krimm M, Wong KR, Liu S, Daugherty, West JW and Lowman HB: Tumor-specific activation of EGFR-targeting probody enhances therapeutic index. Sci Transl Med 5: 207ra144, 2013.
120. Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C and Brinkmann U: Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 25: 571-580, 2012.
121. Parr C, Sanders AJ and Jiang WG: Hepatocyte growth factor activation inhibitors - therapeutic potential in cancer. Anticancer Agents Med Chem 10: 47-57, 2010.
122. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006.
123. Sun J, Pons J and Craik CS: Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42: 892-900, 2003.
124. Farady CJ, Egea PF, Schneider EL, Darragh MR and Craik CS: Structure of a Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol 380 : 351-360, 2008.
125. Hayden, C.E: News. Personalized cancer therapy gets closer. Genetic testing allows doctors to select best treatment. Nature 458: 131-132, 2009.
126. Simon R and Roychowdhury S: Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12: 358-369, 2013.
127. Martini M, Vecchione L, Siena S, Tejpar S and Bardelli A: Targeted therapies: how personal should we go? Nat Rev Clin Oncol 9: 87-97, 2011.
128. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The Protein Data Bank (www.pdb.org). Nucleic Acids Res 28: 235-242, 2000.
129. Accelrys Software Incorp., Discovery Studio Modeling Environment, Release 3.1, San Diego: Accelrys Software Inc., 2007.